Literature DB >> 22549157

Overexpression of RalBP1 in colorectal cancer is an independent predictor of poor survival and early tumor relapse.

Nathan M Mollberg1, Gunnar Steinert, Maximillian Aigner, Alexander Hamm, Fang-Ju Lin, Heike Elbers, Christoph Reissfelder, Jürgen Weitz, Markus W Buchler, Moritz Koch.   

Abstract

The non-ABC transport protein RalBP1 has been shown to be overexpressed in various cancer cell lines and implicated in the process of metastasis formation, but its expression in tissue samples and prognostic significance has not been shown. In this study matched tumor-mucosa tissue samples from 78 CRC patients were investigated. The RalBP1 mRNA and protein levels were quantified by real-time quantitative PCR (qPCR) and ELISA. RalBP1 was found to be overexpressed in tumor at the mRNA level both overall (p = 0.027), and for stages I (p = 0.024), II (p = 0.038) and IV (p = 0.004). At the protein level, RalBP1 was only significantly overexpressed in stage IV patients (p = 0.018). Expression of RalBP1 mRNA and protein were inversely correlated (r = 0.4173; p = 0.0004). Multivariate Cox regression analysis including sex, age, stage, grade, and nodal status as covariates showed that overexpression of RalBP1 protein, but not mRNA, was an independent predictor of both decreased disease free survival (p = 0.016, RR = 6.892) and overall survival (p = 0.039, RR = 5.986). These results suggest that RalBP1 protein is an independent predictor of poor survival and early relapse for CRC patients. Owing to its multifunctional intermediary role in cell survival, chemotherapeutic resistance, and metastasis formation, RalBP1 represents a promising novel therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22549157      PMCID: PMC3408974          DOI: 10.4161/cbt.20087

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  33 in total

1.  mTOR-independent translational control of the extrinsic cell death pathway by RalA.

Authors:  Amith Panner; Jean L Nakamura; Andrew T Parsa; Pablo Rodriguez-Viciana; Mitchel S Berger; David Stokoe; Russell O Pieper
Journal:  Mol Cell Biol       Date:  2006-08-07       Impact factor: 4.272

Review 2.  Ral: mediator of membrane trafficking.

Authors:  Ellen M van Dam; Phillip J Robinson
Journal:  Int J Biochem Cell Biol       Date:  2006-05-09       Impact factor: 5.085

3.  RalBP1 is necessary for metastasis of human cancer cell lines.

Authors:  Zhong Wu; Charles Owens; Nidhi Chandra; Kay Popovic; Mark Conaway; Dan Theodorescu
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

4.  The epsin family of endocytic adaptors promotes fibrosarcoma migration and invasion.

Authors:  Brian G Coon; John Burgner; Jacques H Camonis; R Claudio Aguilar
Journal:  J Biol Chem       Date:  2010-08-13       Impact factor: 5.157

5.  Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer.

Authors:  Sharad S Singhal; Archana Sehrawat; Mukesh Sahu; Preeti Singhal; Rit Vatsyayan; Poorna Chandra Rao Lelsani; Sushma Yadav; Sanjay Awasthi
Journal:  Int J Cancer       Date:  2010-03-15       Impact factor: 7.396

6.  Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (Ral-binding protein 1).

Authors:  Sharad S Singhal; Jyotsana Singhal; Sushma Yadav; Seema Dwivedi; Paul J Boor; Yogesh C Awasthi; Sanjay Awasthi
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

7.  Increased expression of cdc2 inhibits transport function of RLIP76 and promotes apoptosis.

Authors:  Sharad S Singhal; Sushma Yadav; Rit Vatsyayan; Pankaj Chaudhary; Jozef Borvak; Jyotsana Singhal; Sanjay Awasthi
Journal:  Cancer Lett       Date:  2009-04-17       Impact factor: 8.679

8.  Activation of the RalGEF/Ral pathway promotes prostate cancer metastasis to bone.

Authors:  JuanJuan Yin; Claire Pollock; Kirsten Tracy; Monika Chock; Philip Martin; Michael Oberst; Kathleen Kelly
Journal:  Mol Cell Biol       Date:  2007-08-20       Impact factor: 4.272

9.  RALA and RALBP1 regulate mitochondrial fission at mitosis.

Authors:  David F Kashatus; Kian-Huat Lim; Donita C Brady; Nicole L K Pershing; Adrienne D Cox; Christopher M Counter
Journal:  Nat Cell Biol       Date:  2011-08-07       Impact factor: 28.824

10.  RLIP76 (RalBP1) is an R-Ras effector that mediates adhesion-dependent Rac activation and cell migration.

Authors:  Lawrence E Goldfinger; Celeste Ptak; Erin D Jeffery; Jeffrey Shabanowitz; Donald F Hunt; Mark H Ginsberg
Journal:  J Cell Biol       Date:  2006-09-11       Impact factor: 10.539

View more
  9 in total

Review 1.  Ral GTPases in tumorigenesis: emerging from the shadows.

Authors:  David F Kashatus
Journal:  Exp Cell Res       Date:  2013-07-02       Impact factor: 3.905

2.  P300 regulates the human RLIP76 promoter activity and gene expression.

Authors:  Archana Sehrawat; Sushma Yadav; Yogesh C Awasthi; Alakananda Basu; Charles Warden; Sanjay Awasthi
Journal:  Biochem Pharmacol       Date:  2013-02-16       Impact factor: 5.858

Review 3.  RLIP76 Targeted Therapy for Kidney Cancer.

Authors:  Sharad S Singhal; Jyotsana Singhal; James Figarola; David Horne; Sanjay Awasthi
Journal:  Pharm Res       Date:  2015-05-29       Impact factor: 4.200

Review 4.  RLIP76 Inhibition: A Promising Developmental Therapy for Neuroblastoma.

Authors:  Sharad S Singhal; Lokesh Nagaprashantha; Preeti Singhal; Sulabh Singhal; Jyotsana Singhal; Sanjay Awasthi; David Horne
Journal:  Pharm Res       Date:  2017-04-06       Impact factor: 4.200

Review 5.  Fixing the GAP: The role of RhoGAPs in cancer.

Authors:  Gabriel Kreider-Letterman; Nicole M Carr; Rafael Garcia-Mata
Journal:  Eur J Cell Biol       Date:  2022-02-10       Impact factor: 6.020

6.  Complexity of molecular alterations impacts pancreatic cancer prognosis.

Authors:  Ivonne Regel; Bo Kong; Philipp Bruns; Christoph W Michalski; Jörg Kleeff
Journal:  World J Gastrointest Oncol       Date:  2013-01-15

7.  RLIP depletion induces apoptosis associated with inhibition of JAK2/STAT3 signaling in melanoma cells.

Authors:  Sharad S Singhal; Atish Mohanty; Prakash Kulkarni; David Horne; Sanjay Awasthi; Ravi Salgia
Journal:  Carcinogenesis       Date:  2021-05-28       Impact factor: 4.944

8.  CS-PEI/Beclin-siRNA Downregulate Multidrug Resistance Proteins and Increase Paclitaxel Therapeutic Efficacy against NSCLC.

Authors:  Wangta Liu; Yu-Lun Lo; Chin Hsu; Yi-Ting Wu; Zi-Xian Liao; Wen-Jeng Wu; Yi-Jou Chen; Chieh Kao; Chien-Chih Chiu; Li-Fang Wang
Journal:  Mol Ther Nucleic Acids       Date:  2019-06-29

9.  Endocytic adaptor protein epsin is elevated in prostate cancer and required for cancer progression.

Authors:  Kandice L Tessneer; Satish Pasula; Xiaofeng Cai; Yunzhou Dong; Xiaolei Liu; Lili Yu; Scott Hahn; John McManus; Yiyuan Chen; Baojun Chang; Hong Chen
Journal:  ISRN Oncol       Date:  2013-04-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.